Merck & Co., Inc. (VIE:MRK)
Austria · Delayed Price · Currency is EUR | Market Cap | 315.97B +84.8% |
| Revenue (ttm) | 58.27B +4.6% |
| Net Income | 2.78B -80.7% |
| EPS | 1.11 -80.4% |
| Shares Out | n/a |
| PE Ratio | 113.77 |
| Forward PE | 16.70 |
| Dividend | 2.94 (2.30%) |
| Ex-Dividend Date | Sep 15, 2026 |
| Volume | 78 |
| Open | 128.46 |
| Previous Close | 127.90 |
| Day's Range | 126.88 - 128.46 |
| 52-Week Range | 66.70 - 134.36 |
| Beta | 0.23 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 29, 2026 |
About Merck & Co.
Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. The company also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock produ... [Read more]
Financial Performance
In 2025, Merck & Co.'s revenue was $65.01 billion, an increase of 1.31% compared to the previous year's $64.17 billion. Earnings were $18.25 billion, an increase of 6.64%.
Financial numbers in USD Financial StatementsNews
Merck says CHMP adopts positive opinion on Keytruda/Padcev combination
Merck (MRK) announced the European Medicines Agency’s Committee for Medicinal Products for Human Use adopted a positive opinion recommending approval of Keytruda, Merck’s anti-PD-1 therapy, in combina...
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as Perioperative Treatment for Adults With Resectable Muscle-Invasive Bladder Cancer (MIBC)
RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the European Medicines Agency's Committee for Medicinal Products for Human Use (...
Moderna's AI-Built Cancer Vaccine Clears Phase 3 With Merck
Moderna built an artificial intelligence that reads a patient's tumor and decides what that patient's medicine should be. That approach just cleared its biggest test.
Merck & Co. Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
Transformation is progressing with strong product launches, positive clinical data, and business development driving growth. Pipeline assets like INT and sac-TMT offer significant upside, while LIPFENDRA is positioned for broad access. AI and global innovation are enhancing R&D efficiency.
Perspective Therapeutics announces trial collaboration agreement with Merck
Perspective Therapeutics (CATX) announced a clinical trial collaboration agreement with Merck (MRK). The agreement supports the evaluation of Perspective’s targeted alpha-particle therapy PSV359 in co...
REVOLUTIONIZING HEALTHCARE: Tempus partners with Merck on AI-driven precision medicine
Tempus CEO Eric Lefkofsky discusses the company's artificial intelligence-driven precision medicine partnership with Merck on ‘The Claman Countdown.'
Merck price target raised to $172 from $150 at HSBC
HSBC raised the firm’s price target on Merck (MRK) to $172 from $150 and keeps a Buy rating on the shares. The firm adjusted targets in the healthcare group to…
Merck & Co. Transcript: Wells Fargo 21st Annual Healthcare Conference
Significant progress was reported in portfolio transformation, with projected human health revenues rising to over $70B by the mid-2030s. Oncology and non-oncology pipelines are advancing, with new launches, robust clinical data, and strategic investments supporting long-term growth.
The Big 3: ROST, MRK, AAPL
Don Kaufman (@Theotrade) calls the U.S. Treasury's $6 billion bond buyback plan "nominal" to investors seeking relief as the inflation picture gets wider by the day. However, he sees bearish opportuni...
AI & Robotics in 2026: 16 Recent Developments for Investors
If AI and robotics suddenly feel like they are moving faster, August gave investors plenty of evidence that the pace really is accelerating. We saw longer-running agents, faster and cheaper inference,...
Leerink ups Merck price target on pipeline momentum
Leerink analyst Daina Graybosch raised the firm’s price target on Merck (MRK) to $161 from $127 and keeps an Outperform rating on the shares. The firm cites Merck’s “strong” pipeline…
Merck price target raised to $161 from $127 at Leerink
Leerink raised the firm’s price target on Merck (MRK) to $161 from $127 and keeps an Outperform rating on the shares.
Merck price target raised to $170 from $146 at Guggenheim
Guggenheim raised the firm’s price target on Merck (MRK) to $170 from $146 and keeps a Buy rating on the shares, driven mainly by increased sales estimates for intismeran autogene…
Merck to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
RAHWAY, N.J.--(BUSINESS WIRE)--Merck to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference.
Merck price target raised to $170 from $150 at Wells Fargo
Wells Fargo raised the firm’s price target on Merck (MRK) to $170 from $150 and keeps an Overweight rating on the shares. The firm says its survey of 22 specialists…
India's Cipla, China's Qilu partner for US launch of Merck's Keytruda biosimilar
India's Cipla said on Thursday its U.S. unit entered an exclusive partnership with China's Qilu Pharmaceutical to license a biosimilar version of Merck's cancer drug Keytruda for the U.S. market.
Why Moderna's Cancer Vaccine Matters to Investors
Healthcare is moving away from the traditional model of mass-produced, one-size-fits-all treatments toward individualized therapies. This evolution in medicine aims to provide treatments that are not ...
Merck to Participate in the Wells Fargo 21st Annual Healthcare Conference
RAHWAY, N.J.--(BUSINESS WIRE)--Merck to Participate in the Wells Fargo 21st Annual Healthcare Conference.
Success after a century of failures: Inside Moderna and Merck's cancer vaccine breakthrough
Stephane Bancel, CEO of Moderna , was at a Lebanese restaurant celebrating a friend's birthday late on August 13 when he got the call.
Explainer: How the Merck/Moderna cancer vaccine works and possible barriers to wide use
The personalized cancer vaccine being developed by Moderna and Merck has boosted hopes that mRNA technology could open up a new avenue of treatment, but the available evidence is still limited.
What Happens if Moderna's Cancer Vaccine Works
Moderna and Merck's personalized cancer vaccine could transform cancer treatment and create a multibillion-dollar market, but investors may already be pricing in much of its potential.
Emily Field: Large pharma companies are going to continue looking at biotech
Emily Field, Head of U.S. Biopharma Equity Research at Barclays, says biotech is gaining momentum as M&A returns, capital markets reopen and breakthroughs in cancer vaccines fuel investor interest.
Why Is Merck Stock Still An Undervalued Mega-Cap In Pharma?
This article was written by Doug Nathman, with research by his team at Trefis.
Moderna is paring back gains, but Merck stock remains a buy
Moderna (MRNA) shares are paring back some of their recent gains on Thursday morning – but a Morgan Stanley analyst believes Merck (MRK) stock remains a buy following blockbuster cancer drug trial res...
Thursday's First Moves: Analysts Mixed on MRNA & MRK Rally, AAP & DE Earnings
Diane King Hall discusses the sharp sell-off in Advance Auto Parts (AAP) as the guidance shows strong headwinds. Deere (DE) offered plenty of strength in its earnings as construction revenues rise.